Distribution of human papillomavirus genotypes among cervical intraepithelial neoplasia and invasive cancers in Macao

Journal of Medical Virology

Volumn 82, Issue 9, 2010, Pages 1600-1605

  Hlaing, Thazin ^a   Yip, Yuk Ching ^b   Ngai, Karry L K ^c   Vong, Heong Ting ^b   Wong, Sio In ^a   Ho, Wendy C S ^c   Batalha, Sellma L S C ^a   Chan, Paul K S ^c  

^a Macau Special Administrative Region   (China)

^b Macao Special Administrative Region of the People's Republic of China   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Asia; Cervical intraepithelial neoplasia; China; Epidemiology; Genotype; Human papillomavirus; Invasive cervical cancer; Macao; Vaccine impact

Indexed keywords

WART VIRUS VACCINE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 54; HUMAN TISSUE; MACAO; MIXED INFECTION; RISK ASSESSMENT; UTERINE CERVIX; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; HUMANS; MACAU; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES;

EID: 77956589804     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21847     Document Type: Article

References (24)

1. Bao YP, Li N, Smith JS, Qiao YL, ACCPAB Members. 2008. Human papillomavirus type distribution in women from Asia: A metaanalysis. Int J Gynecol Cancer 18:71-79.
2. Chan PK, Chan DP, To KF, Yu MY, Cheung JL, Cheng AF. 2001. Evaluation of extraction methods from paraffin wax embedded tissues for PCR amplification of human and viral DNA. J Clin Pathol 54:401-403.
3. Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, Chan MY, Cheung JL, Cheng AF. 2002. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer 94:1249-1253.
4. Chan PK, Cheung TH, Tam AO, Lo KW, Yim SF, Yu MM, To KF, Wong YF, Cheung JL, Chan DP, Hui M, Ip M. 2006. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 118:243-245.
5. Chan PK, Ho WC, Yu MY, Pong WM, Chan AC, Chan AK, Cheung TH, Wong MC, To KF, Ng HK. 2009. Distribution of human papillomavirus types in cervical cancers in Hong Kong: Current situation and changes over the last decades. Int J Cancer 125:1671-1677.
6. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. 2003a. Humanpapillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 88:63-73.
7. Clifford GM, Smith JS, Aguado T, Franceschi S. 2003b. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis. Br J Cancer 89:101-105.
8. Ding DC, Hsu HC, Huang RL, Lai HC, Lin CY, Yu MH, Chu TY. 2008. Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan: An indication of viral oncogenic potential. Eur J Obstet Gynecol Reprod Biol 140:245-251.
9. FUTURE II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915-1927.
10. Health Bureau, Macao SAR Government. 2006. Annual report of Macao cancer registry, 2005. http://www.ssm.gov.mo/design/home-e-fs.htm (accessed on Jan 25, 2010).
11. Ho CM, Chien TY, Huang SH, Lee BH, Chang SF. 2006. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol 102:54-60.
12. Huang S, Afonina I, Miller BA, Beckmann AM. 1997. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer 4:408-411.
13. Muñoz N. 2000. Human papillomavirus and cancer: The epidemiological evidence. J Clin Virol 19:1-5.
14. Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527. (Pubitemid 36159887)
15. Muñoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A. 2009. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial. Lancet 373: 1949-1957.
16. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsagué X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamram U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyg F, Wieting SL, Lehtinen MO, Dubin G. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161-2170.
17. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsagué X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
18. Prétet JL, Jacquard AC, Saunier M, Clavel C, Dachez R, Gondry J, Pradat P, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D, EDiTH Study Group. 2008. Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with cervical intraepithelial neoplasia grade 2/3 and invasive cervical cancer: The EDiTH III study. Gynecol Oncol 110:179-184.
19. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. 2007. Human papillomavirus and cervical cancer. Lancet 370:890-907.
20. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 121:621-632.
21. Suba EJ, Raab SS. 2010. on behalf of the Viet/American Cervical Cancer Prevention Project. HPV vaccination: Waiting for evidence of effectiveness. Lancet 375:639-640.
22. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
23. Wu EQ, Zhang GN, Yu XH, Ren Y, Fan Y, Wu YG, Kong W, Zha X. 2008. Evaluation of high-risk human papillomaviruses types distribution in cervical cancer in Sichuan Province in China. BMC Cancer 8:202.
24. zur Hausen H. 2002. Papillomavirus and cancer: From basic studies to clinical application. Nat Rev Cancer 2:342-350.